Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Mackall Website

Crystal L. Mackall, M.D.

Selected Publications

1)  van Den Brink M, Leen AM, Baird K, Merchant M, Mackall C, Bollard CM.
Enhancing immune reconstitution: from bench to bedside.
Biol. Blood Marrow Transplant. 19: S79-83, 2013.
[Journal]
2)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
[Journal]
3)  Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.
Front Oncol. 2: 194, 2012.
[Journal]
4)  Lundström W, Fewkes NM, Mackall CL.
IL-7 in human health and disease.
Semin. Immunol. 24: 218-24, 2012.
[Journal]
5)  Orentas RJ, Lee DW, Mackall C.
Immunotherapy targets in pediatric cancer.
Front Oncol. 2: 3, 2012.
[Journal]
6)  Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH, Meyers PA, Widemann BC, Tsokos M, Mackall CL.
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
J. Clin. Oncol. 30: 4141-7, 2012.
[Journal]
7)  Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL.
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.
Biol. Blood Marrow Transplant. 18: 698-707, 2012.
[Journal]
8)  Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Clin. Cancer Res. 18: 2780-90, 2012.
[Journal]
9)  Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, Mackall CL.
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
J. Immunother. 34: 187-95, 2011.
[Journal]
10)  Mackall CL, Fry TJ, Gress RE.
Harnessing the biology of IL-7 for therapeutic application.
Nat. Rev. Immunol. 11: 330-42, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/19/2013.